Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159054 · ClinicalTrials.gov registry record · NA
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
A NA study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT01159054 is a NA study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 22 participants.
The verdict
NCT01159054, a NA study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Patients with kidney failure on hemodialysis have an extremely high rate of cardiovascular disease including atherosclerotic cardiovascular disease. This, at least in part, is due to the chronic inflammatory status usually seen in these patients. Here we try to see if treatment with extended release nicotinic acid (Niaspan) can reduce their overall inflammatory burden (in general) and the atherosclerotic plaque inflammation (in particular).
Interventions
- DRUG Extended Release Nicotinic Acid (Niaspan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159054
The ClinicalTrials.gov registry entry for NCT01159054 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Extended Release Nicotinic Acid (Niaspan) is the first listed.
NCT01159054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159054 about?
NCT01159054 is a clinical study titled "Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid". Patients with kidney failure on hemodialysis have an extremely high rate of cardiovascular disease including atherosclerotic cardiovascular disease. This, at least in part, is due to the chronic inflammatory status usually seen in these patients. Here we try to see if treatment with extended release...
What is the current status of trial NCT01159054?
This trial is currently terminated. It is a NA study. The enrollment target is 22 participants. The study started on 2010-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01159054?
The interventions under investigation include: Extended Release Nicotinic Acid (Niaspan) (DRUG).
Who is sponsoring clinical trial NCT01159054?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.